Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: Using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey

Autor: Yusuke Awa, Hiroomi Nakatsu, Tatsuya Okano, Yuzo Furuya, Hiroyoshi Suzuki, Masashi Yano, Ken-ichi Egoshi, Takemasa Ohki, Tomohiko Ichikawa, Kazuo Mikami, Satoru Hamano, Sho Ota
Rok vydání: 2006
Předmět:
Zdroj: International Journal of Urology. 13:1202-1206
ISSN: 0919-8172
Popis: Aim: To examine the efficiency of α1-blocker treatment on disease-specific and generic quality of life (QOL) in men with clinically diagnosed benign prostatic hyperplasia (BPH), the improvement of QOL scores with International prostate symptom score (I-PSS) and Rand Medical Outcomes Study 36-item Health Survey (SF-36) was prospectively analyzed. Methods: A total of 68 newly diagnosed patients with symptomatic BPH that satisfied all inclusion and none of the exclusion criteria were prospectively recruited. All patients received 0.2 mg/day of tamsulosin for 12 weeks. All patients underwent pretreatment documentation of lower urinary tract symptoms (LUTS) and assessment of symptom-specific QOL. Symptoms and general health-related QOL (HRQOL) were assessed using the I-PSS and SF-36, respectively. Also, other objective variables, such as prostate volume, maximal urinary flow and postvoid residual urine volume, were evaluated. Results: After 12 weeks, decrease in I-PSS was 27% compared with baseline (from 16.4 ± 7.18 to 11.9 ± 7.56). All questionnaires in the I-PSS showed improvement after tamsulosin treatment and the I-PSS QOL score was improved from 4.51 ± 1.14 to 3.17 ± 1.38 (P
Databáze: OpenAIRE